Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Revenues down 4% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck
 
3Q Revenues: $11.0 billion (-4%)

3Q Earnings: $1.1 billion (-35%)

YTD Revenues: $32.7 billion (-8%)

YTD Earnings: $3.7 billion (-31%)

Comments: Pharmaceutical sales were down 4% to $9.5 billion in the quarter, impacted by a 2% negative impact due to foreign exchange and loss of exclusivity for Singulair (-53% to $280 million), Maxalt (-76% to $40 million), Temodar (-29% to $162 million) and Cozaar/Hyzaar (-20% to $238 million). Remicade sales were up 17% to $574 million. Gardasil sales were up 15% to $665 million. Simponi sales were up 47% to $126 million. Isentress sales were up 7% to $427 million. Animal Health sales totaled $800 million in the quarter, down 2% and Consumer Care sales were $443 million, down 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters